E7070 in Treating Patients With Solid Tumors

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of E7070 in treating patients who have solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
• Treatments: N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed solid tumor that is not amenable to standard therapy

• No brain involvement or leptomeningeal disease

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• WHO 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 9 g/dL

Hepatic:

• Bilirubin less than 1.5 mg/dL

• Liver function tests no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)

Renal:

• Creatinine no greater than 1.4 mg/dL OR

• Creatinine clearance at least 60 mL/min

Other:

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No active bacterial infections (e.g., abscess or fistulae)

• No other nonmalignant disease that precludes protocol therapy

• No history of alcoholism, drug addiction, or psychotic disorders that preclude participation

• No glaucoma

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• At least 4 weeks since prior immunotherapy

Chemotherapy:

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

• No other concurrent antitumor drugs

Endocrine therapy:

• At least 4 weeks since prior anticancer hormonal therapy

Radiotherapy:

• At least 4 weeks since prior radiotherapy (6 weeks for extensive radiotherapy)

• No concurrent radiotherapy (except localized palliative radiotherapy)

Surgery:

• Not specified

Other:

• No concurrent sulfonylurea agent for diabetes or antiarrhythmic agents

• No other concurrent investigational drugs